IL2 and ovarian carcinoma: Another promising yet challenging area of immunotherapy in ovarian cancer is cytokine therapy, which aims to enhance the immune response by administering or modifying specific cytokines, such as IL-2, IL-12 and IL-15, that activate natural killer (NK) and cytotoxic T lymphocytes [84].